Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.34 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 7/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL114430 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| SCHEMBL29482181 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| SCHEMBL29789670 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| SCHEMBL616862 | 0.96 | ALDH1A1 (0.52) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| Hydrochloric Acid SCHEMBL30670337 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| Hydrochloric Acid SCHEMBL28840014 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| Hydrochloric Acid SCHEMBL27243769 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| Hydrochloric Acid SCHEMBL28153388 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| SCHEMBL27822750 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 | |
| SCHEMBL9939143 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105061286-B | A kind of synthetic method of alkynyl substituted azoles | 上海蓝木化工有限公司 | 2017-11-24 | — | — | CN | claimed |
| CN-105384674-B | A kind of synthetic method of diphenyl substituted indole compound | 甘肃皓骏药业有限公司 | 2017-08-25 | — | — | CN | claimed |
| CN-105294412-B | Catalytic synthesis method of indan-1, 3-dione compound | 南陵县生产力促进中心有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-105001130-A | Synthesis method of 3-aryl-2-cyclopenten-1-one compound | ZHANG LINPING | 2015-10-28 | — | — | CN | claimed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3481814-B1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | UNIV ROCKEFELLER (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3141548-B9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMA (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3141548-B1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMA (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3141548-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2017-03-15 | — | — | EP | disclosed |
| CN-105001130-B | A kind of synthetic method of 3-aryl-2-cyclopentene-1-one compound | 青岛大学附属医院 | 2016-10-05 | — | — | CN | disclosed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-8796453-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2729465-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20130303764-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-11-14 | — | — | US | disclosed |
| US-8513414-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013006634-A9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013006634-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | CHRM2 4570/4885CHRM1 4336/4885CHRM3 4388/4885 |
| US-20130303764-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | CHRM2 4570/4885CHRM1 4336/4885CHRM3 4388/4885 |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | ITGAV, ITGB3, ITGA4 | CHRM2 3165/4885CHRM1 3214/4885CHRM3 2608/4885 |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | CHRM2 4570/4885CHRM1 4336/4885CHRM3 4388/4885 |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | ITGAV, ITGB3, ITGA4 | CHRM2 3165/4885CHRM1 3214/4885CHRM3 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.